Skip to main content

Menopausal Syndrome

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
estradiol plus MPAPhase 41 trial
Active Trials
NCT01698164Unknown1,200
Unimed Pharma
Unimed PharmaSlovakia - Bratislava
1 program
1
MELSMONPhase 31 trial
Active Trials
NCT01931748Completed104Est. Apr 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
UNION therapeuticsestradiol plus MPA
Unimed PharmaMELSMON

Clinical Trials (2)

Total enrollment: 1,304 patients across 2 trials

Multi-centre Clinical Trial on Hormone Replacement Treatment in China

Start: Dec 20081,200 patients
Phase 4Unknown

A Randomized, Double-Blind, Parallel, Non-Inferiority, Multicenter Trial Evaluate the Efficacy and Safety of UNCNT Compared to MELSMON in Female With Menopausal Syndrome

Start: Apr 2013Est. completion: Apr 2014104 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.